ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

Velcade Improves Survival In Relapsed Multiple Myeloma

July 29, 2005

FDA To Issue “Complete Response” Letters To Drug Sponsors.

July 11, 2008

ACS Urges Bush To Increase NCI Budget.

January 19, 2007

New Grant Program To Fund Partnerships Between Academia, Industry, Non-Profits

March 14, 2003

Wyngaarden Law With Appointment Report; DeVita Tells Congress “We’re Addressing The Issue Internally”

March 20, 1987

CTEP-Approved Trials For the Month of June

June 28, 2013